
STOK Stock Forecast & Price Target
STOK Analyst Ratings
Bulls say
Stoke Therapeutics has established a promising outlook due to its innovative TANGO approach and the significant progress of its lead program, zorevunersen, which demonstrates substantial potential in treating Dravet syndrome. The recent collaboration with Biogen not only validates zorevunersen's drug profile and enhances commercialization prospects but also alleviates financial pressures by sharing development costs, boosting the confidence in the drug's success. Additionally, the robust clinical data showing sustained seizure reduction and improvements across various behavioral measures further underpins the company's growth potential, providing a strong foundation for future financial performance.
Bears say
Stoke Therapeutics Inc faces significant financial and operational risks that contribute to a negative outlook on its stock. The company may encounter challenges related to key patent protections, which could undermine its market success and lead to valuation declines. Additionally, substantial uncertainties surrounding the clinical development and commercialization of its drug candidates, along with the necessity of raising additional capital, further exacerbate the risks of investment in the company.
This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
STOK Analyst Forecast & Price Prediction
Start investing in STOK
Order type
Buy in
Order amount
Est. shares
0 shares